From scientific discovery to treatments for rare diseases - The view from the National Center for Advancing Translational Sciences - Office of Rare Diseases Research

Orphanet Journal of Rare Diseases

Volumn 13, Issue 1, 2018, Pages

  Kaufmann, Petra ^a   Pariser, Anne R ^a   Austin, Christopher ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical studies; Interdisciplinary research; Investigational therapies; National Center for Advancing Translational Sciences; Rare diseases

Indexed keywords

ARTICLE; CLINICAL ASSESSMENT TOOL; CONFERENCE PAPER; COORDINATION; DATA SHARING; GENETICS; GENOTYPE; GOVERNMENT; HEALTH PROMOTION; HUMAN; INFORMATION SHARING; INFRASTRUCTURE; INTEGRATION; INTERSECTORAL COLLABORATION; MEDICAL INFORMATION; MEDICAL RESEARCH; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES TOOLKIT; NATIONAL HEALTH ORGANIZATION; OFFICE OF RARE DISEASES RESEARCH; PATIENT CARE; PATIENT FOCUSED THERAPY DEVELOPMENT TOOLKIT; PERSONALIZED MEDICINE; PHENOTYPE; PRACTICE GUIDELINE; PUBLIC-PRIVATE PARTNERSHIP; RARE DISEASE; SCIENCE; STAKEHOLDER ENGAGEMENT; STANDARD; TREATMENT INDICATION; UNITED STATES; WORKSHOP; INTERDISCIPLINARY RESEARCH; PROCEDURES; TRANSLATIONAL RESEARCH;

HUMANS; INTERDISCIPLINARY RESEARCH; RARE DISEASES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85056125716     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-018-0936-x     Document Type: Article

References (27)

1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of F&D costs. J Health Econ. 2016;47:20-33.
2. Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M. Di-Stefano-Pappas et al. safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661-72.
3. Mendell JR, Al-Zaidy S, Shelll R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713-22.
4. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani G, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-58.
5. Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase tiral. Lancet. 2016;388:476-87.
6. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723-32.
7. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637-47.
8. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. NN Engl J Med. 2014;371:1507-17.
9. Neelapu SS, Locke FL, Barlett NL, Lekakis LJ, Miklos DB, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531-44.
10. Nature Biotechnology News. First in vivo human genome editing trial. Nat Biotechnol. 2018;36:5.
11. Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378:1479-93.
12. Cheng K, Gupta SK, Kantor S, Kuhl JT, Aceves SS, Bonis PA, et al. Creating a multi-center rare disease consortium - the consortium of eosinophilic gastrointestinal disease researchers (CEGIR). Transl Sci Rare Dis. 2017;18:141-55.
13. The National Academies of Sciences and Engineering: The CTSA program at NIH: opportunities for advancing clinical and. Translational Research (2013). https://ncats.nih.gov/advisory/council/subcomm/ctsaiom. Accessed 24 Sept 2018.
14. SMART IRB: Suppoiting single IRB review. Advancing collaboration research (2018). https://smartirb.org/. Accessed 24 Sept 2018.
15. Heemskirk J, Farkas R, Kaufmann P. Neuroscience networking: linking discovery to drugs. Neuropsychopharmacology. 2012;3:287-9.
16. Kaufmann P, O'Rourke PP. Central institutional review board review for an academic trial network. Acad Med. 2015;90:321-3.
17. Merkel PA, Manion M, Gopal-Srivastava R, Groft S, Jinnah HA, Robertson D, Krischer JP. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Rare Diseases Clinical Research Network Orphanet J Rare Dis. 2016;18(11):66.
18. NIH NCATS. NCATS Toolkit for Patient-Focused Therapy Development (2017). https://rarediseases.info.nih.gov/toolkit. Accessed 24 Sept 2018.
19. rd edition. Rockville, AHRQ 2014 Accessed 2/12/2018.
20. Lewis J, Snyder M, Hyatt-Knorr H. Marking 15 years of the genetic and rare diseases information center. Transl Sci Rare Dis. 2017;25:77-88.
21. Patient-centered Outcomes Research Institute. Rare Diseases (2018). https://www.pcori.org/research-results/topics/rare-diseases. Accessed 24 Sept 2018.
22. Austin CP, Cutillo CM, Lau LP, et al. Future of rare diseases research 2017-2027: an IRDiRC perspective, CTS. Clinical and Translational Science. 2018;11:21-7.
23. NIH, U.S. National Library of medicine. Common Data Element (CDE) Resource Portal (2016). https://www.nlm.nih.gov/cde/. Accessed 24 Sept 2018.
24. Sheehan J, Hirschfeld S, Foster E, et al. Improving the value of clinical research through the use of common data elements. Clin Trials. 2016;13:671-6.
25. Robinson PN, Mundolos S. The human phenotype ontology. Clin Genet. 2010;77:525-34.
26. Kohler S, Vasilevsky NA, Engelstad M, Foster E, McMurry J, Ayme S, Baynam G, Bello SM, Koerkoel CF, Boycott KM, et al. The human phenotype ontology in 2017. Nucleic Acids Res. 2017;45(D1):D865-76.
27. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377:62-70.